- Agilent Technologies ( NYSE: A ) said on Wednesday it will acquire Avida Biomed to expand into clinical research and diagnostics markets for cancer research.
- Avida Biomed is an early-stage life sciences company that develops target enrichment workflows for clinical researchers using next-generation sequencing approaches to study cancer.
- Avida's chemistries and assays are compatible with Agilent’s automation platforms including Magnis and Bravo, which will help in research experiments and routine sample testing.
- Avida's technology will help to develop new approaches for a variety of applications including biomarker discovery, patient selection for clinical trials, diagnosis and prognosis, therapy selection, and disease recurrence.
For further details see:
Agilent to acquire Avida for cancer research